InsiderSignalSign in

← Insider buys

IMVT

Immunovant, Inc. · Healthcare

Insiders bought $350.0M of Immunovant, Inc. in the last 12 months

1 insider bought on 1 day.

$350.0MBought, 12 mo

$15.5MSold, 12 mo

$5.9BMarket cap

IMVT over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

Roivant Sciences Ltd.Director and 10% owner · 1 day$350.0M

IMVT after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

139 insider filings since 2020, newest first

Jay S Stout · Chief Technology Officer

$75K−1.3%3d ago

Jay S Stout · Chief Technology Officer

$122K−1.9%Oct 9

Tuyl Christopher Van · Chief Legal Officer

$43K−0.8%Oct 9

Melanie Gloria · Chief Operating Officer

$72K−1.0%Oct 9

Eric Venker · Chief Executive Officer

$120K−1.3%Oct 5

Tuyl Christopher Van · Chief Legal Officer

$103K−1.6%Sep 25

Atul Pande · Director

$65K−1.3%Aug 28

Melanie Gloria · Chief Operating Officer

$135K−1.4%Aug 21

Atul Pande · Director

$60K−1.3%Jul 24

Tiago Girao · Chief Financial Officer

$263K−2.7%Jul 24

Jay S Stout · Chief Technology Officer

$111K−1.4%Jul 24

Melanie Gloria · Chief Operating Officer

$81K−0.9%Jul 10

Tuyl Christopher Van · Chief Legal Officer

$48K−0.7%Jul 10

Jay S Stout · Chief Technology Officer

$138K−1.6%Jul 10

Eric Venker · Chief Executive Officer

$119K−1.2%Jul 6

Melanie Gloria · Chief Operating Officer

$679K−7.3%Jun 26

Jay S Stout · Chief Technology Officer

$1.5M−15.9%Jun 26

Tuyl Christopher Van · Chief Legal Officer

$683K−9.0%Jun 26

Tiago Girao · Chief Financial Officer

$385K−3.9%Jun 26

Atul Pande · Director

$57K−1.3%Jun 26

Tuyl Christopher Van · Chief Legal Officer

$93K−1.4%Jun 22

Atul Pande · Director

$51K−1.3%Jun 16

Andrew J. Fromkin · Director

$7.4M−74.9%May 29

Melanie Gloria · COO

$101K−1.0%May 22

Atul Pande · Director

$192K−4.0%May 20

Jay S Stout · CTO

$82K−1.0%Apr 24

Tuyl Christopher Van · General Counsel

$128K−3.0%Apr 10

Melanie Gloria · COO

$217K−3.0%Apr 10

Jay S Stout · CTO

$252K−4.0%Apr 10

Eric Venker · CEO

$343K−42.0%Apr 3

Tuyl Christopher Van · General Counsel

$72K−2.0%Mar 20

Melanie Gloria · COO

$90K−2.0%Feb 27

Jay S Stout · CTO

$51K−1.0%Jan 23

Jay S Stout · CTO

$32K−1.0%Jan 9

Tuyl Christopher Van · General Counsel

$291K−7.0%Dec 19

Roivant Sciences Ltd. · Director and 10% owner

$350.0M+17.0%Dec 12

Andrew J. Fromkin · Director

$517K−21.0%Dec 3

Douglas J. Hughes · Director

$349K−11.0%Dec 3

Melanie Gloria · COO

$298K−7.0%Nov 21

Roivant Sciences Ltd. · Director and 10% owner

$336.9M+21.0%Jan 15

Mark S. Levine · General Counsel

$93K−1.0%Nov 22

William L. Macias · Chief Medical Officer

$85K−1.0%Nov 22

Eva Renee Barnett · CFO

$106K−1.0%Nov 22

Peter Salzmann · CEO

$425K−2.0%Nov 22

Jay S Stout · CTO

$81K−2.0%Oct 25

Mark S. Levine · General Counsel

$129K−1.0%Oct 25

Michael Geffner · Chief Medical Officer

$94K−2.0%Oct 25

Peter Salzmann · CEO

$262K−1.0%Oct 18

William L. Macias · Chief Medical Officer

$92K−1.0%Oct 18

Mark S. Levine · General Counsel

$82K−1.0%Oct 18

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.